These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33861086)

  • 1. First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate.
    Sun H; Monenschein H; Schiffer HH; Reichard HA; Kikuchi S; Hopkins M; Macklin TK; Hitchcock S; Adams M; Green J; Brown J; Murphy ST; Kaushal N; Collia DR; Moore S; Ray WJ; English NM; Carlton MBL; Brice NL
    J Med Chem; 2021 Jul; 64(14):9875-9890. PubMed ID: 33861086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease.
    Brice NL; Schiffer HH; Monenschein H; Mulligan VJ; Page K; Powell J; Xu X; Cheung T; Burley JR; Sun H; Dickson L; Murphy ST; Kaushal N; Sheardown S; Lawrence J; Chen Y; Bartkowski D; Kanta A; Russo J; Hosea N; Dawson LA; Hitchcock SH; Carlton MB
    J Pharmacol Exp Ther; 2021 Jun; 377(3):407-416. PubMed ID: 33795395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson's Disease.
    Margolin DH; Brice NL; Davidson AM; Matthews KL; Carlton MBL
    J Pharmacol Exp Ther; 2022 Apr; 381(1):33-41. PubMed ID: 35110393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease.
    Oeckl P; Hengerer B; Ferger B
    Exp Neurol; 2014 Jul; 257():1-9. PubMed ID: 24747358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of endogenous inverse agonists for G protein-coupled receptor 6.
    Shrader SH; Song ZH
    Biochem Biophys Res Commun; 2020 Feb; 522(4):1041-1045. PubMed ID: 31818461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased susceptibility of G-protein coupled receptor 6 deficient mice to MPTP neurotoxicity.
    Oeckl P; Ferger B
    Neuroscience; 2016 Nov; 337():218-223. PubMed ID: 27651149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease.
    Das B; Vedachalam S; Luo D; Antonio T; Reith ME; Dutta AK
    J Med Chem; 2015 Dec; 58(23):9179-95. PubMed ID: 26555041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPR3 and GPR6, novel molecular targets for cannabidiol.
    Laun AS; Song ZH
    Biochem Biophys Res Commun; 2017 Aug; 490(1):17-21. PubMed ID: 28571738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and optimization of a novel CNS penetrant series of mGlu
    Kent CN; Fulton MG; Stillwell KJ; Dickerson JW; Loch MT; Rodriguez AL; Blobaum AL; Boutaud O; Rook JL; Niswender CM; Conn PJ; Lindsley CW
    Bioorg Med Chem Lett; 2021 Apr; 37():127838. PubMed ID: 33556572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis, and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinson's Disease.
    Elmabruk A; Das B; Yedlapudi D; Xu L; Antonio T; Reith MEA; Dutta AK
    ACS Chem Neurosci; 2019 Jan; 10(1):396-411. PubMed ID: 30301349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol.
    Laun AS; Shrader SH; Brown KJ; Song ZH
    Acta Pharmacol Sin; 2019 Mar; 40(3):300-308. PubMed ID: 29941868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.
    Lesuisse D; Malanda A; Peyronel JF; Evanno Y; Lardenois P; De-Peretti D; Abécassis PY; Barnéoud P; Brunel P; Burgevin MC; Cegarra C; Auger F; Dommergue A; Lafon C; Even L; Tsi J; Luc TPH; Almario A; Olivier A; Castel MN; Taupin V; Rooney T; Vigé X
    Bioorg Med Chem Lett; 2019 Apr; 29(7):929-932. PubMed ID: 30773432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect.
    Tang L; Huang C; Zhong J; He J; Guo J; Liu M; Xu JP; Wang HT; Zhou ZZ
    Eur J Med Chem; 2019 Apr; 168():221-231. PubMed ID: 30822711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson's disease rat model.
    Fatemi I; Abdollahi A; Shamsizadeh A; Allahtavakoli M; Roohbakhsh A
    Acta Neuropsychiatr; 2021 Feb; 33(1):15-21. PubMed ID: 32967746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
    Machado-Filho JA; Correia AO; Montenegro AB; Nobre ME; Cerqueira GS; Neves KR; Naffah-Mazzacoratti Mda G; Cavalheiro EA; de Castro Brito GA; de Barros Viana GS
    Behav Brain Res; 2014 May; 264():116-25. PubMed ID: 24525422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPR6 Structural Insights: Homology Model Construction and Docking Studies.
    Isawi IH; Morales P; Sotudeh N; Hurst DP; Lynch DL; Reggio PH
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32046081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and optimization of piperine analogues as neuroprotective agents for the treatment of Parkinson's disease via the activation of Nrf2/keap1 pathway.
    Wang L; Cai X; Shi M; Xue L; Kuang S; Xu R; Qi W; Li Y; Ma X; Zhang R; Hong F; Ye H; Chen L
    Eur J Med Chem; 2020 Aug; 199():112385. PubMed ID: 32402936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes.
    Elbassuoni EA; Ahmed RF
    Neurochem Int; 2019 Dec; 131():104583. PubMed ID: 31654678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Iron(II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic Agent for Parkinson's Disease.
    Das B; Kandegedara A; Xu L; Antonio T; Stemmler T; Reith MEA; Dutta AK
    ACS Chem Neurosci; 2017 Apr; 8(4):723-730. PubMed ID: 28106982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
    Mishra A; Singh S; Tiwari V; Bano S; Shukla S
    Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.